IP Verse

Kymab Limited opposition analysis

COMPANY ANALYSIS

Latest oppositions filed by Kymab Limited

Patent Number:
EP3456190
Title:
Antibody Producing Non-Human Mammals
Applicant:
MERUS N.V.
Opposition Date:
Aug 19, 2022
Patent Number:
EP3626819
Title:
Transgenic Mouse Which Produces Hybrid Antibodies Containing Human Variable Regions And Mouse Constant Regions
Applicant:
REGENERON PHARMACEUTICALS, INC.
Opposition Date:
Dec 22, 2021
Patent Number:
EP2738258
Title:
Adam6 Mice
Applicant:
REGENERON PHARMACEUTICALS, INC.
Opposition Date:
Jun 25, 2020
Patent Number:
EP2578688
Title:
Adam6 Mice
Applicant:
REGENERON PHARMACEUTICALS, INC.
Opposition Date:
May 4, 2020
Patent Number:
EP3085780
Title:
Producing Hybrid Antibodies Containing Human Variable Regions And Rodent Constant Regions
Applicant:
REGENERON PHARMACEUTICALS, INC.
Opposition Date:
Jun 28, 2019
Patent Number:
EP3085779
Title:
Method Of Modifying Eukaryotic Cells
Applicant:
REGENERON PHARMACEUTICALS, INC.
Opposition Date:
Apr 5, 2019
Patent Number:
EP2482849
Title:
Combination Immunotherapy For The Treatment Of Cancer
Applicant:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Opposition Date:
Mar 6, 2019
Patent Number:
EP2786657
Title:
A Method Of Producing An Antibody Comprising A Human Variable Region And A Rodent Constant Region.
Applicant:
REGENERON PHARMACEUTICALS, INC.
Opposition Date:
Nov 7, 2018
Patent Number:
EP2786657
Title:
A Method Of Producing An Antibody Comprising A Human Variable Region And A Rodent Constant Region.
Applicant:
REGENERON PHARMACEUTICALS, INC.
Opposition Date:
Mar 21, 2018

Latest patents of Kymab Limited opposed by its competitors

Patent:
EP3622813
Grant Date:
Jun 19, 2024
Title:
Animal Models And Therapeutic Molecules
Oppositions:
1
Patent:
EP3028564
Grant Date:
Jan 24, 2024
Title:
Animal Models And Therapeutic Molecules
Oppositions:
1
Patent:
EP3047022
Grant Date:
Dec 27, 2023
Title:
Expression Vector Production And High-Throughput Cell Screening
Oppositions:
1
Patent:
EP2757875
Grant Date:
Mar 22, 2023
Title:
Manipulation Of Immunoglobulin Gene Diversity And Multi-Antibody Therapeutics
Oppositions:
1
Patent:
EP2792236
Grant Date:
Mar 22, 2023
Title:
Animal Models And Therapeutic Molecules
Oppositions:
1
Patent:
EP2798950
Grant Date:
Mar 22, 2023
Title:
Animal Models And Therapeutic Molecules
Oppositions:
1
Patent:
EP2989894
Grant Date:
Dec 14, 2022
Title:
Use Of Fertile Transgenic Animals For Producing Antibodies Bearing Human Variable Regions
Oppositions:
1
Patent:
EP3311661
Grant Date:
Apr 20, 2022
Title:
Manipulation Of Immunoglobulin Gene Diversity And Multi-Antibody Therapeutics
Oppositions:
1
Patent:
EP3241435
Grant Date:
May 26, 2021
Title:
Animal Models And Therapeutic Molecules
Oppositions:
1
Patent:
EP3418379
Grant Date:
Dec 9, 2020
Title:
Methods, Cells & Organisms
Oppositions:
1

Competitors of Kymab Limited

REGENERON PHARMACEUTICALS, INC.

BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

JAMES POOLE LIMITED

Want to track Kymab Limited?

Feel free to send us a message here and we will get back to you